Kymera Therapeutics Overview
Kymera Therapeutics Target Price
Analysts' 12-month price predictions for KYMR.
Share Price
$30.07
Average Target Price
$54.00
79.6% upside
79.6% upside1 analysts in the last 4 months
High: $54 | Low: $54
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-02-28 | H.C. Wainwright | $54 | 79.6% upside |  |
| 2024-12-05 | BMO CapitalEtzer Darout | $55 | 82.9% upside | |
| 2024-12-02 | Wells FargoDerek Archila | $57 | 89.6% upside | |
| 2024-09-27 | OppenheimerJeff Jones | $56 | 86.2% upside | |
| 2024-08-26 | Wolfe ResearchAndy Chen | $65 | 116.2% upside | |
| 2024-08-08 | H.C. WainwrightAndrew Fein | $60 | 99.5% upside | |
| 2024-06-17 | H.C. WainwrightAndrew Fein | $46 | 53% upside | |
| 2024-05-23 | Piper SandlerEdward Tenthoff | $56 | 86.2% upside | |
| 2024-05-03 | OppenheimerJeff Jones | $52 | 72.9% upside | |
| 2023-01-03 | Wells Fargo | $42 | 39.7% upside | |
| 2022-12-19 | Morgan Stanley | $41 | 36.3% upside | |
| 2022-12-16 | Goldman Sachs | $52 | 72.9% upside | |
| 2022-12-15 | Leerink Partners | $31 | 3.1% upside | |
| 2022-12-06 | Morgan StanleyMichael Turits | $45.2 | 50.3% upside | |
| 2022-12-06 | Credit SuisseRichard Law | $32 | 6.4% upside | |
| 2022-08-29 | Morgan Stanley | $37 | 23% upside | |
| 2022-08-10 | Credit Suisse | $61 | 102.9% upside | |
| 2022-05-04 | Morgan Stanley | $35 | 16.4% upside | |
| 2022-05-04 | Credit Suisse | $60 | 99.5% upside | |
| 2021-05-20 | UBSEliana Merle | $80 | 166% upside | |